SEC annual filings · Chemicals and Drugs
Which companies in chemicals and drugs have the most revenue in the SEC data we read?
In 2025, 221 companies in chemicals and drugs that have had revenue of 100 million dollars or more are ranked; Johnson & Johnson reported the most, $94.2 billion. The newest annual report in the data is for the fiscal year ended .
Right now
Johnson & Johnson reported the most revenue in 2025, $94.2 billion.
221 companies in chemicals and drugs are ranked for 2025.
Share of revenueOurs
Together they reported $1.2 trillion of revenue, 4.6% of the revenue of all $25.7 trillion reported by the ranked companies.
A fiscal year is counted in the calendar year most of its days fall in, as the SEC labels it, so a year that ended on 31 January 2026 is 2025 here; the market totals count a year in the year it ends in, so their sum for the same year holds other fiscal years.
As filed
Facts as filed with the SEC, and our arithmetic on them. Not investment advice.
Total assets are the figure the SEC data holds for the fiscal year end.
Understanding the ranking
Where it stands today
Johnson & Johnson reported $94.2 billion, the most in 2025.
How is the ranking made?
The ranking lists companies by the revenue they filed with the SEC for their fiscal year in 2025, the largest first.
Read more
A company is in the ranking when its latest annual report shows revenue of 100 million dollars or more, and stays in it afterwards. A company that has stopped filing keeps its page and is not ranked.
The numbers behind the chart
Which companies in chemicals and drugs reported the most revenue?221 companies
| Company | Rank | Symbol | Revenue | Profit or loss | Total assets |
|---|---|---|---|---|---|
| Johnson & Johnson | 1 | JNJ | $94.2B | $26.8B | $199B |
| Procter & Gamble Co | 2 | PG | $84.3B | $16.0B | $125B |
| Eli Lilly & Co | 3 | LLY | $65.2B | $20.6B | $112B |
| Merck & Co., Inc. | 4 | MRK | $65.0B | $18.3B | $137B |
| Pfizer Inc | 5 | PFE | $62.6B | $7.77B | $208B |
| AbbVie Inc. | 6 | ABBV | $61.2B | $4.23B | $134B |
| Bristol-Myers Squibb Co | 7 | BMY | $48.2B | $7.05B | $90.0B |
| Abbott Laboratories | 8 | ABT | $44.3B | $6.52B | $86.7B |
| DOW Inc. | 9 | DOW | $40.0B | – | $58.5B |
| Amgen Inc | 10 | AMGN | $36.8B | $7.71B | $90.6B |
| Linde plc | 11 | LIN | $34.0B | $6.90B | $86.8B |
| LyondellBasell Industries N.V. | 12 | LYB | $30.2B | −$738M | $34.0B |
| Gilead Sciences, Inc. | 13 | GILD | $29.4B | $8.51B | $59.0B |
| Colgate-Palmolive Co | 14 | CL | $20.4B | $2.13B | $16.3B |
| Teva Pharmaceutical Industries Ltd | 15 | TEVA | $17.3B | $1.41B | $40.7B |
| Ecolab Inc. | 16 | ECL | $16.1B | $2.08B | $24.7B |
| PPG Industries Inc | 17 | PPG | $15.9B | $1.58B | $22.1B |
| Kenvue Inc. | 18 | KVUE | $15.1B | $1.47B | $27.1B |
| Regeneron Pharmaceuticals, Inc. | 19 | REGN | $14.3B | $4.50B | $40.6B |
| Estee Lauder Companies Inc | 20 | EL | $14.3B | −$1.13B | $19.9B |
| Viatris Inc | 21 | VTRS | $14.3B | – | $37.2B |
| Mosaic Co | 22 | MOS | $12.1B | $541M | $24.5B |
| Air Products & Chemicals, Inc. | 23 | APD | $12.0B | −$395M | $41.1B |
| Vertex Pharmaceuticals Inc | 24 | VRTX | $12.0B | $3.95B | $25.6B |
| Westlake Corp | 25 | WLK | $11.2B | −$1.51B | $20.0B |
Show 196 more rows
| Company | Rank | Symbol | Revenue | Profit or loss | Total assets |
|---|---|---|---|---|---|
| International Flavors & Fragrances Inc | 26 | IFF | $10.9B | – | $25.5B |
| Bausch Health Companies Inc. | 27 | BHC | $10.3B | $157M | $26.4B |
| Biogen Inc. | 28 | BIIB | $9.89B | $1.29B | $29.4B |
| Celanese Corp | 29 | CE | $9.54B | −$1.17B | $21.7B |
| Zoetis Inc. | 30 | ZTS | $9.47B | $2.67B | $15.5B |
| Eastman Chemical Co | 31 | EMN | $8.75B | $474M | $14.9B |
| RPM International Inc | 32 | RPM | $7.86B | $662M | $8.34B |
| Clorox Co | 33 | CLX | $7.10B | $824M | $5.56B |
| CF Industries Holdings, Inc. | 34 | CF | $7.08B | – | $14.1B |
| DuPont de Nemours, Inc. | 35 | DD | $6.85B | $88.0M | $21.6B |
| Olin Corp | 36 | OLN | $6.78B | −$101M | $7.33B |
| Organon & Co. | 37 | OGN | $6.22B | $187M | $12.9B |
| Church & Dwight Co Inc | 38 | CHD | $6.20B | $737M | $8.91B |
| Coty Inc. | 39 | COTY | $5.89B | −$381M | $11.9B |
| Chemours Co | 40 | CC | $5.81B | −$386M | $7.38B |
| Huntsman Corp | 41 | HUN | $5.68B | −$284M | $7.01B |
| Sealed Air Corp | 42 | – | $5.36B | $506M | $7.01B |
| BeOne Medicines Ltd. | 43 | ONC | $5.34B | $287M | $8.19B |
| Albemarle Corp | 44 | ALB | $5.14B | −$511M | $16.4B |
| Axalta Coating Systems Ltd. | 45 | AXTA | $5.12B | $379M | $7.60B |
| Elanco Animal Health Inc | 46 | ELAN | $4.71B | −$232M | $13.4B |
| IDEXX Laboratories Inc | 47 | IDXX | $4.30B | $1.06B | $3.35B |
| Jazz Pharmaceuticals plc | 48 | JAZZ | $4.27B | −$356M | $11.7B |
| Perrigo Co plc | 49 | PRGO | $4.25B | −$1.43B | $8.54B |
| Union Carbide Corp | 50 | – | $3.99B | $560M | $4.52B |
| Solstice Advanced Materials Inc. | 51 | SOLS | $3.89B | $237M | $5.67B |
| Alnylam Pharmaceuticals, Inc. | 52 | ALNY | $3.71B | $314M | $4.97B |
| Cabot Corp | 53 | CBT | $3.71B | $331M | $3.81B |
| Fuller H B Co | 54 | FUL | $3.47B | $152M | $5.18B |
| FMC Corp | 55 | FMC | $3.47B | −$2.24B | $9.69B |
| Scotts Miracle-Gro Co | 56 | SMG | $3.41B | $145M | $2.74B |
| Avient Corp | 57 | AVNT | $3.26B | $81.9M | $6.03B |
| BioMarin Pharmaceutical Inc | 58 | BMRN | $3.22B | $349M | $7.59B |
| United Therapeutics Corp | 59 | UTHR | $3.18B | $1.33B | $7.88B |
| Amneal Pharmaceuticals, Inc. | 60 | AMRX | $3.02B | $72.1M | $3.68B |
| Trinseo plc | 61 | TSEOQ | $2.97B | −$546M | $2.28B |
| Tronox Holdings plc | 62 | TROX | $2.90B | −$470M | $6.22B |
| Neurocrine Biosciences Inc | 63 | NBIX | $2.86B | $479M | $4.63B |
| QuidelOrtho Corp | 64 | QDEL | $2.73B | – | $5.77B |
| NewMarket Corp | 65 | NEU | $2.73B | $419M | $3.49B |
| Element Solutions Inc | 66 | ESI | $2.55B | $191M | $5.10B |
| Royalty Pharma plc | 67 | RPRX | $2.38B | $771M | $19.6B |
| Stepan Co | 68 | SCL | $2.33B | $46.9M | $2.36B |
| Exelixis, Inc. | 69 | EXEL | $2.32B | $783M | $2.84B |
| Sarepta Therapeutics, Inc. | 70 | SRPT | $2.20B | −$713M | $3.35B |
| Green Plains Inc. | 71 | GPRE | $2.09B | −$121M | $1.58B |
| Qiagen N.V. | 72 | QGEN | $2.09B | $425M | $6.28B |
| Valhi Inc | 73 | VHI | $2.08B | −$57.6M | $2.63B |
| Minerals Technologies Inc | 74 | MTX | $2.07B | −$18.4M | $3.47B |
| Edgewell Personal Care Co | 75 | EPC | $1.96B | $25.4M | $3.76B |
| Moderna, Inc. | 76 | MRNA | $1.94B | −$2.82B | $12.3B |
| Hexcel Corp | 77 | HXL | $1.89B | $109M | $2.70B |
| Kronos Worldwide Inc | 78 | KRO | $1.86B | −$111M | $1.82B |
| Orion S.A. | 79 | OEC | $1.81B | −$70.0M | $1.91B |
| Innospec Inc. | 80 | IOSP | $1.78B | – | $1.83B |
| PTC Therapeutics, Inc. | 81 | PTCT | $1.73B | $683M | $2.90B |
| e.l.f. Beauty, Inc. | 82 | ELF | $1.64B | $26.3M | $2.39B |
| Sensient Technologies Corp | 83 | SXT | $1.61B | $134M | $2.24B |
| Lantheus Holdings, Inc. | 84 | LNTH | $1.54B | $234M | $2.23B |
| AdvanSix Inc. | 85 | ASIX | $1.52B | $49.3M | $1.71B |
| Interparfums Inc | 86 | IPAR | $1.49B | $208M | $1.59B |
| Alkermes plc. | 87 | ALKS | $1.48B | $242M | $2.49B |
| Keenova Therapeutics plc | 88 | – | $1.43B | −$490M | $5.63B |
| Halozyme Therapeutics, Inc. | 89 | HALO | $1.40B | $317M | $2.53B |
| Phibro Animal Health Corp | 90 | PAHC | $1.30B | $48.3M | $1.36B |
| Curaleaf Holdings, Inc. | 91 | CURLF | $1.27B | −$231M | $2.85B |
| Indivior Pharmaceuticals, Inc. | 92 | INDV | $1.24B | $210M | $1.20B |
| Bio-Techne Corp | 93 | TECH | $1.22B | $73.4M | $2.56B |
| Trulieve Cannabis Corp. | 94 | TRLV | $1.18B | −$116M | $2.70B |
| Ingevity Corp | 95 | NGVT | $1.17B | −$167M | $1.65B |
| Westlake Chemical Partners LP | 96 | WLKP | $1.17B | $48.7M | $1.26B |
| Novavax Inc | 97 | NVAX | $1.12B | $440M | $1.18B |
| Prestige Consumer Healthcare Inc. | 98 | PBH | $1.09B | $190M | $3.49B |
| CSW Industrials, Inc. | 99 | CSW | $1.08B | $112M | $2.32B |
| Acadia Pharmaceuticals Inc | 100 | ACAD | $1.07B | $391M | $1.56B |
| Balchem Corp | 101 | BCPC | $1.04B | $155M | $1.69B |
| Apellis Pharmaceuticals, Inc. | 102 | – | $1.00B | $22.4M | $1.08B |
| Ionis Pharmaceuticals Inc | 103 | IONS | $944M | −$381M | $3.52B |
| USANA Health Sciences Inc | 104 | USNA | $925M | $10.8M | $743M |
| Alto Ingredients, Inc. | 105 | ALTO | $918M | – | $389M |
| Tilray Brands, Inc. | 106 | TLRY | $915M | −$121M | $2.33B |
| ANI Pharmaceuticals Inc | 107 | ANIP | $883M | $78.0M | $1.44B |
| BioCryst Pharmaceuticals Inc | 108 | BCRX | $875M | $264M | $514M |
| Neogen Corp | 109 | NEOG | $870M | −$7.90M | $3.35B |
| Harmony Biosciences Holdings, Inc. | 110 | HRMY | $868M | $159M | $1.27B |
| Myriad Genetics Inc | 111 | MYGN | $825M | −$366M | $707M |
| Rogers Corp | 112 | ROG | $811M | −$61.8M | $1.43B |
| Oddity Tech Ltd | 113 | ODD | $810M | $111M | $1.14B |
| Collegium Pharmaceutical, Inc | 114 | COLL | $781M | $63.0M | $1.66B |
| Corcept Therapeutics Inc | 115 | CORT | $761M | $99.7M | $837M |
| Emergent BioSolutions Inc. | 116 | EBS | $743M | $52.6M | $1.32B |
| Repligen Corp | 117 | RGEN | $738M | $48.9M | $2.95B |
| Pacira BioSciences, Inc. | 118 | PCRX | $726M | $7.00M | $1.26B |
| Ecovyst Inc. | 119 | ECVT | $724M | −$71.1M | $1.26B |
| Amphastar Pharmaceuticals, Inc. | 120 | AMPH | $720M | $98.1M | $1.63B |
| Supernus Pharmaceuticals, Inc. | 121 | SUPN | $719M | −$38.6M | $1.45B |
| Kiniksa Pharmaceuticals International, plc | 122 | KNSA | $678M | $59.0M | $764M |
| Ultragenyx Pharmaceutical Inc. | 123 | RARE | $673M | −$575M | $1.53B |
| Cresco Labs Inc. | 124 | CRLBF | $656M | −$135M | $1.20B |
| Perimeter Solutions, Inc. | 125 | PRM | $653M | −$206M | $2.65B |
| REX American Resources Corp | 126 | REX | $650M | $83.0M | $798M |
| Axsome Therapeutics, Inc. | 127 | AXSM | $638M | −$183M | $690M |
| Amicus Therapeutics, Inc. | 128 | – | $634M | −$27.1M | $950M |
| WD-40 Co | 129 | WDFC | $620M | $91.0M | $476M |
| TG Therapeutics, Inc. | 130 | TGTX | $616M | $447M | $1.06B |
| LSB Industries, Inc. | 131 | LXU | $615M | $24.6M | $1.17B |
| Yatsen Holding Ltd | 132 | YSG | $615M | −$11.6M | $550M |
| OPKO Health, Inc. | 133 | OPK | $607M | −$226B | $1.93B |
| Insmed Inc | 134 | INSM | $606M | −$1.28B | $2.26B |
| CVR Partners, LP | 135 | UAN | $606M | $98.7M | $969M |
| Catalyst Pharmaceuticals, Inc. | 136 | – | $589M | $214M | $1.10B |
| Organogenesis Holdings Inc. | 137 | ORGO | $564M | $37.0M | $599M |
| HUTCHMED (China) Ltd | 138 | HCM | $549M | $457M | $1.75B |
| Mirum Pharmaceuticals, Inc. | 139 | MIRM | $521M | −$23.4M | $843M |
| American Vanguard Corp | 140 | AVD | $515M | −$49.9M | $597M |
| ADMA Biologics, Inc. | 141 | ADMA | $510M | $147M | $624M |
| BridgeBio Pharma, Inc. | 142 | BBIO | $502M | – | $936M |
| Ascend Wellness Holdings, Inc. | 143 | AAWH | $501M | – | $908M |
| Travere Therapeutics, Inc. | 144 | TVTX | $491M | −$25.5M | $605M |
| Nature's Sunshine Products Inc | 145 | NATR | $480M | $19.5M | $261M |
| Zai Lab Ltd | 146 | ZLAB | $460M | −$176M | $1.17B |
| Tarsus Pharmaceuticals, Inc. | 147 | TARS | $451M | −$66.0M | $562M |
| Olaplex Holdings, Inc. | 148 | – | $423M | −$9.25M | $1.50B |
| Innoviva, Inc. | 149 | INVA | $411M | – | $1.64B |
| Ardelyx, Inc. | 150 | ARDX | $407M | −$62.0M | $502M |
| Esperion Therapeutics, Inc. | 151 | – | $403M | −$22.7M | $466M |
| Immunocore Holdings plc | 152 | IMCR | $400M | −$35.5M | $1.07B |
| Krystal Biotech, Inc. | 153 | KRYS | $389M | $205M | $1.33B |
| Sinovac Biotech Ltd | 154 | SVA | $386M | – | $8.54B |
| Luxfer Holdings plc | 155 | LXFR | $385M | $7.70M | $370M |
| Twist Bioscience Corp | 156 | TWST | $377M | −$77.7M | $642M |
| Arcutis Biotherapeutics, Inc. | 157 | ARQT | $376M | −$16.1M | $433M |
| MannKind Corp | 158 | MNKD | $349M | $5.86M | $792M |
| Evolus, Inc. | 159 | EOLS | $297M | −$51.6M | $226M |
| Ironwood Pharmaceuticals Inc | 160 | IRWD | $296M | $24.0M | $397M |
| Rigel Pharmaceuticals Inc | 161 | RIGL | $294M | – | $514M |
| Xeris Biopharma Holdings, Inc. | 162 | XERS | $292M | – | $384M |
| Aurinia Pharmaceuticals Inc. | 163 | AUPH | $283M | – | $752M |
| Adaptive Biotechnologies Corp | 164 | ADPT | $277M | −$59.5M | $513M |
| Vericel Corp | 165 | VCEL | $276M | $16.5M | $488M |
| Harrow, Inc. | 166 | HROW | $272M | −$5.14M | $399M |
| Waldencast plc | 167 | MLKMF | $272M | −$230M | $746M |
| Vireo Growth Inc. | 168 | VREOF | $269M | −$68.1M | $817M |
| Ligand Pharmaceuticals Inc | 169 | LGND | $268M | $124M | $1.56B |
| Jushi Holdings Inc. | 170 | JUSH | $263M | −$68.6M | $422M |
| Arvinas, Inc. | 171 | ARVN | $263M | −$81.0M | $718M |
| Schrodinger, Inc. | 172 | SDGR | $256M | −$103M | $726M |
| Arcus Biosciences, Inc. | 173 | RCUS | $247M | −$353M | $1.14B |
| Flotek Industries Inc | 174 | FTK | $237M | $30.5M | $220M |
| Vaxart, Inc. | 175 | VXRT | $237M | – | $186M |
| Akebia Therapeutics, Inc. | 176 | AKBA | $236M | −$5.30M | $377M |
| AnaptysBio, Inc | 177 | ANAB | $235M | −$13.2M | $364M |
| Lifevantage Corp | 178 | LFVN | $229M | $9.80M | $72.0M |
| Puma Biotechnology, Inc. | 179 | PBYI | $228M | $31.1M | $216M |
| IDEAYA Biosciences, Inc. | 180 | IDYA | $219M | −$114M | $1.11B |
| Vanda Pharmaceuticals Inc. | 181 | VNDA | $216M | −$221M | $489M |
| Amarin Corp plc | 182 | AMRN | $214M | −$38.8M | $671M |
| Aemetis, Inc | 183 | AMTX | $198M | −$77.0M | $260M |
| Cronos Group Inc. | 184 | CRON | $193M | −$2.90M | $1.20B |
| biote Corp. | 185 | BTMD | $192M | $27.0M | $108M |
| Rhythm Pharmaceuticals, Inc. | 186 | RYTM | $190M | −$0.20M | $480M |
| Maravai Lifesciences Holdings, Inc. | 187 | MRVI | $186M | −$131M | $771M |
| Stoke Therapeutics, Inc. | 188 | STOK | $184M | −$6.88M | $418M |
| Glass House Brands Inc. | 189 | GLAS | $182M | −$29.7M | $319M |
| Cryoport, Inc. | 190 | CYRX | $176M | $78.3M | $765M |
| Phathom Pharmaceuticals, Inc. | 191 | PHAT | $175M | – | $259M |
| Syndax Pharmaceuticals Inc | 192 | SNDX | $172M | −$285M | $530M |
| REGENXBIO Inc. | 193 | RGNX | $170M | −$194M | $453M |
| Ginkgo Bioworks Holdings, Inc. | 194 | DNA | $170M | −$0.31M | $1.12B |
| Gevo, Inc. | 195 | GEVO | $161M | −$33.8M | $719M |
| MariMed Inc. | 196 | MRMD | $160M | −$14.5M | $203M |
| Liquidia Corp | 197 | LQDA | $158M | −$68.9M | $328M |
| NLI Holdings, Inc. | 198 | NL | $158M | −$37.8M | $464M |
| Day One Biopharmaceuticals, Inc. | 199 | – | $158M | −$107B | $508M |
| Heron Therapeutics, Inc. | 200 | HRTX | $155M | −$20.0M | $256M |
| MacroGenics Inc | 201 | MGNX | $150M | – | $257M |
| Elite Pharmaceuticals Inc | 202 | ELTP | $149M | $44.9M | $138M |
| Karyopharm Therapeutics Inc. | 203 | KPTI | $146M | −$196M | $108M |
| Highwater Ethanol LLC | 204 | – | $141M | $16.3M | $89.9M |
| Beam Therapeutics Inc. | 205 | BEAM | $140M | −$80.0M | $1.48B |
| Natural Alternatives International Inc | 206 | NAII | $130M | −$13.6M | $152M |
| Niagen Bioscience, Inc. | 207 | NAGE | $129M | $17.4M | $106M |
| Xencor Inc | 208 | XNCR | $126M | −$91.9M | $875M |
| Monte Rosa Therapeutics, Inc. | 209 | GLUE | $124M | −$38.6M | $449M |
| Atara Biotherapeutics, Inc. | 210 | ATRA | $121M | $32.7M | $20.2M |
| Arq, Inc. | 211 | ARQ | $120M | −$52.6M | $231M |
| Assertio Holdings, Inc. | 212 | – | $119M | −$30.4M | $267M |
| Gyre Therapeutics, Inc. | 213 | GYRE | $117M | $9.88M | $220M |
| Agenus Inc | 214 | AGEN | $114M | −$3.08M | $227M |
| UroGen Pharma Ltd. | 215 | URGN | $110M | −$153M | $200M |
| Century Therapeutics, Inc. | 216 | IPSC | $109M | −$9.58M | $224M |
| Mannatech Inc | 217 | MTEX | $108M | −$15.2M | $30.0M |
| Theravance Biopharma, Inc. | 218 | – | $107M | $106M | $486M |
| Zevra Therapeutics, Inc. | 219 | ZVRA | $106M | $83.2M | $285M |
| Zymeworks Inc. | 220 | ZYME | $106M | −$81.1M | $347M |
| Sutro Biopharma, Inc. | 221 | STRO | $102M | −$191M | $174M |
The table scrolls sideways; the first column stays in place.
Which other companies does the group hold?2 companies
What does the ranking leave out, and where is it from?Limits and source
What this number cannot tell you
- Only companies with a revenue figure for the ranking year that passes our checks are ranked, the largest first; equal figures share a rank.
- A company's figures are its own. A company that files together with a parent or a subsidiary is ranked on its own figure, so the same business can appear twice, and a sum of revenue counts it twice.
- Total assets are shown only when the SEC data dates them within ten days of the fiscal year end, and profit only when its period ends within sixty days of it.
- A dash is a gap. Either the company did not report that figure for that year, or the figure failed one of our checks and is not shown. The dash says which when it is pointed at.
Observed .
Page updated